Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery and Structure–Activity Relationship of Potent and Selective Covalent Inhibitors of Transglutaminase 2 for Huntington’s Disease

6 Jan 2012

Abstract excerpt

Tissue transglutaminase 2 (TG2) is a multifunctional protein primarily known for its calcium-dependent enzymatic protein cross-linking activity via isopeptide bond formation between glutamine and lysine residues. TG2 overexpression and activity have been found to be associated with Huntington's disease (HD); specifically, TG2 is up-regulated in the brains of HD patients and in animal models of the disease....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood properties and coagulation
Share to Genetic Neurodegenerative Diseases
Share to Hereditary Neurological Disorders

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22224594
DOI: 10.1021/jm201310y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery and Structure–Activity Relationship of Potent and Selective Covalent Inhibitors of Transglutaminase 2 for Huntington’s DiseasePMID 22224594Read ↗

Cell-Impermeable Inhibitors Confirm That Intracellular Human Transglutaminase 2 Is Responsible for the Transglutaminase-Associated Cancer Phenotype.Semantic proximity Read ↗

Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington diseaseSemantic proximity Read ↗

Transglutaminase 2 undergoes a large conformational change upon activation.Semantic proximity Read ↗

High-Affinity, Structure-Validated and Selective Macrocyclic Peptide Tools for Chemical Biology Studies of HuntingtinSemantic proximity Read ↗

Silmitasertib, an FDA-designated orphan CK2 Inhibitor, ameliorates neuropathology and motor dysfunction in a Huntington’s disease mouse modelSemantic proximity Read ↗

Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.Semantic proximity Read ↗

Suppression of toxicity of the mutant huntingtin protein by its interacting compound, desonide.Semantic proximity Read ↗

Development of quantitative high-throughput screening assays to identify, validate, and optimize small-molecule stabilizers of misfolded β-glucocerebrosidase with therapeutic potential for Gaucher disease and Parkinson’s diseaseSemantic proximity Read ↗

The role of transglutaminase-2 and its substrates in human diseases.Semantic proximity Read ↗

Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy targetSemantic proximity Read ↗

Anle138b ameliorates pathological phenotypes in mouse and cellular models of Huntington’s diseaseSemantic proximity Read ↗

High-throughput kinetic analysis for target-directed covalent ligand discoverySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.